Kalbe Farma Owned By Conglomerate Boenjamin Setiawan 'Kicks' Emtek Owned By Tycoon Eddy Kusnadi Sariaatmadja From Klikdokter

Illustration. (Photo: Unsplash)

JAKARTA - Pharmaceutical company PT Kalbe Farma Tbk (KLBF) has officially injected additional capital of Rp62.5 billion to one of their subsidiaries, namely PT Karsa Lintas Buana (KLB).

In Kalbe's disclosure of information, quoted on Friday, October 5, the company owned by conglomerate Boenjamin Setiawan explained that the additional capital was directly used by KLB to increase its ownership of PT Medika Komunika Teknologi (MKT). MKT is a company that manages Klikdokter's telemedical services.

"On September 30, 2021, MKT shareholders approved the decision to sell all shares or a total of 1,000 MKT series B shares previously owned by PT Kreatif Media Karya [KMK]. Each of 999 shares was sold to KLB and 1 share was sold to PT Hexpharm Jaya Laboratories [HJL]," said KLBF Corporate Secretary Lukito Kurniawan Gozali.

For information, PT Kreatif Media Karya (KMK), the entity that released its shares to KLB, is a subsidiary of PT Elang Mahkota Teknologi (EMTK) aka the Emtek Group. This means that, along with this transaction, the Emtek Group no longer owns a single share remaining in Klikdokter.

Previously, the Emtek Group, which is a joint venture of KLBF, owned 23.81 percent of Klikdokter's shares. On the other hand, KLB which incidentally stands for KLBF owns about 76.9 percent of the shares.

Now, after the transaction, KLBF's share ownership has increased to 99.98 percent. The remaining 0.02 percent of the remaining shares went to HJL.

"KMK (a subsidiary of the Emtek Group), has no affiliation and/or conflict of interest with the company," added Lukito.

This transaction seems to be part of KLBF's efforts to absorb the remaining capital expenditures this year.

The company said that as of early September 2021, they still had a remaining capital expenditure of around Rp765 billion that needed to be spent this year in order to meet the expansion target.